

ASX Announcement

AdAlta shareholder information sessions

MELBOURNE Australia, 20 July, 2017: AdAlta Limited (ASX: 1AD), the biotechnology company advancing its lead i-body candidate towards clinical development, is pleased to invite shareholders to attend information briefing sessions to discuss the recent results of toxicology studies and other activities to progress lead candidate, AD-114 to human clinical trials.

Shareholder briefing sessions:

The following sessions are available to those shareholders able to attend:

Melbourne:	Friday, 4 th August, 12:00 pm Patersons Stockbroking: Level 15, 333 Collins Street, Melbourne Lunch provided
Perth:	Monday 7 th August, 10:00 am Patersons Stockbroking: Level 23, Exchange Tower, 2 The Esplanade, Perth Morning tea provided
Brisbane:	Tuesday, 8 th August, 4:00 pm Ord Minett: Level 31, 10 Eagle Street, Brisbane Drinks and light refreshments provided
Sydney:	Wednesday, 9th August, 5:30 pm Shaw Stockbroking: Level 15, 60 Castlereagh Street Sydney Drinks and light refreshments provided

Please RSVP to attend

Shareholders wishing to register interest in attending one of the events outlined below should RSVP by COB Monday, 31st July 2017 by phoning Ebony Fietz on +61 0409 018 525 or by using the Contact Us form on the AdAlta website at <http://adalta.com.au/contact-us/> or emailing enquiries@adalta.com.au. At the time of RSVP, please note your: name, email, contact number and which briefing session is of interest (Sydney, Melbourne, Brisbane or Perth.)

The AdAlta team looks forward to seeing those shareholders who are able to attend.

Notes to Editors

About AdAlta

AdAlta Limited is an Australian based drug development company headquartered in Melbourne. The Company is focused on using its proprietary technology platform to generate i-bodies, a new class of protein therapeutics, with applications as therapeutic drugs to treat disease.

I-bodies are a promising, novel class of drugs that offer a new and more effective approach to treating a wide range of human diseases. They are identified and developed using our proprietary technology platform.

We have pioneered a technology that mimics the shape and stability of a crucial antigen-binding domain, that was discovered initially in sharks and then developed as a human protein. The result is a range of unique compounds, now known as i-bodies, for use in treating serious diseases.

AdAlta is developing its lead i-body candidate, AD-114, for the treatment of idiopathic pulmonary fibrosis (IPF) and other human fibrotic diseases, for which current therapies are sub-optimal and there is a high-unmet medical need.

The Company also plans to continue further drug discovery and development directed towards other drug targets and diseases with its i-body technology platform.

Further information can be found at: www.adalta.com.au.

For more information, please contact:

AdAlta Limited

Sam Cobb, CEO

Tel: +61 (0)3 9479 5159

E: s.cobb@adalta.com.au